Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

ARA-290 (Cibinetide)

ARA 290 (cibinetide) is an 11-amino-acid peptide modelled on erythropoietin helix B and designed not to stimulate red-cell production. Two small 28-day placebo-controlled trials in sarcoidosis- and diabetes-associated neuropathy reported mixed results; no approved use was verified in the sources reviewed.

Aliases reviewed
Cibinetide, ARA290, ARA 290, pHBSP, Pyroglutamate helix B surface peptide
Sources checked
2026-10-28
Editorial status
published

Evidence at a glance

Human
LimitedTwo small 28-day placebo-controlled trials reviewed; other published ARA 290 trials not reviewed.
Animal/cell
LimitedRodent studies known only from citations in the two trial reports; not independently reviewed.
Approved medicine
None foundNo approved product found; Canadian DPD searched, other jurisdictions not checked.

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. This concise profile was researched from primary and regulatory records; supplier listings were used only to find the name.

Identity

ARA 290 (cibinetide; pHBSP) is a linear 11-amino-acid peptide modelled on helix B of erythropoietin. PubChem gives its sequence as Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH (pyroglutamyl-EQLERALNSS), formula C51H84N16O21, about 1257 Da. It is not erythropoietin. The diabetes-trial material was a sterile, manufacturer-specific vial formulation, and no source shows it is equivalent to any supplier vial.

Biological mechanism or research interest

It was engineered from erythropoietin as a nonerythropoietic peptide, meaning it was designed not to stimulate red-cell production, and to act on the innate repair receptor. The diabetes trial report describes that receptor as a complex of the beta common receptor (CD131) and erythropoietin receptor subunits. The trial reports discuss it in the context of tissue protection, inflammation and small-fibre neuropathy, and the diabetes trial also measured metabolic control.

Verified approved human uses

No approved human use was verified in the sources reviewed. A Health Canada Drug Product Database active-ingredient search returned no records for "cibinetide" or "ARA 290". FDA, EMA and other jurisdictions were not checked, so this is not a worldwide statement. Being derived from erythropoietin does not give it the status or effects of any erythropoietin medicine.

Investigational human evidence

Two small placebo-controlled studies tested ARA 290 over 28 days. In 38 patients with sarcoidosis-associated small nerve fiber loss (21 ARA 290, 17 placebo), changes in SFNSL symptom scores and 6-minute walk distance favoured ARA 290 over placebo; corneal nerve fiber area rose within the ARA 290 group, with no direct between-group test reported, and intraepidermal nerve fiber density did not change significantly. In a phase 2 study of 48 analyzed adults with type 2 diabetes and painful neuropathy, PainDetect scores and HbA1c improved versus placebo; the HbA1c fall was small (about 0.2 percentage points, in the 42 participants with complete HbA1c measurements), and the authors list already good glycemic control as a limitation. Overall corneal nerve fiber density did not differ between groups; sensory testing and SFNSL did not change in either group; NPSI improved in both groups; the 6-minute walk change was not significant. Both trial reports also cite an earlier small placebo-controlled pilot study in sarcoidosis; it and any later trials were not reviewed here.

Claims of tissue repair, nerve regeneration, anti-inflammatory or metabolic benefit, or general wellness go beyond these short, small, disease-specific studies of trial formulations. The reported positive findings were mainly symptom scores, a small HbA1c change, and within-group or post hoc subgroup corneal measures, while several objective endpoints were null. No phase 3 result or approval was found in the sources reviewed.

Human versus animal or cell evidence

The diabetes trial report cites earlier rodent work: diet-induced insulin-resistant mice (that cited paper is marked retracted in the reference list), Akita diabetic mice, Goto-Kakizaki rats (a conference abstract), and rats and beta common receptor knockout mice in a neuropathic-pain study. The sarcoidosis report cites preclinical neuropathy models in which erythropoietin-derived peptides supported nerve fiber regrowth. These were not independently reviewed here and remain preclinical; they do not show effects in people.

Limitations and known risks

In the diabetes trial, one participant on furosemide, whose furosemide dose had been increased, had previously borderline renal insufficiency that worsened slightly; the safety committee stopped ARA 290, and renal function did not improve during follow-up. Four serious adverse events occurred in the ARA 290 arm, and two were judged possibly related. One death (myocardial infarction after cellulitis) was judged unrelated by the safety committee. The sarcoidosis trial reported no serious adverse events. Treatment lasted only 28 days, both trials were small, and several authors were officers or employees of Araim Pharmaceuticals with stock interests. Long-term safety is unknown, and so are the identity, purity and impurities of catalogue material.

What this profile is—and is not

Concise source review from primary and regulatory records, independently checked for source accuracy; supplier listings were used only to find the name. Recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.